MANTA血管闭合装置在EVAR患者中性能的前瞻性注册研究结果
这项多中心前瞻性观察性非随机研究评估了MANTA血管闭合装置在经皮EVAR患者中的性能,共治疗279例腹股沟。技术成功率为94.3%(263例),不良事件发生率为5.7%(16例),止血中位时间左右侧均为1分0秒。结论认为MANTA在pEVAR患者中安全有效,技术成功率高。
要点
- MANTA在经皮EVAR中技术成功率达94.3%,不良事件率5.7%。
- 止血中位时间左右侧均为1分0秒。
- 术后并发症2.2%,仅0.7%需追加外科手术。
核心结论
- MANTA血管闭合装置在经皮EVAR患者中安全有效,技术成功率高。
研究设计与样本
- 多中心、前瞻性、观察性、非随机研究,纳入符合MANTA使用说明的经皮EVAR患者,2019年1月至2023年11月共治疗279例腹股沟。
主要发现
- 技术成功(部署后5分钟内闭合血管且无再出血、无需额外操作)见于263例腹股沟(94.3%)。
- 不良事件见于16例腹股沟(5.7%)。
- 左右侧股总动脉止血中位时间均为1分0秒(四分位距右侧11分10秒,左侧1分40秒)。
- 因股动脉出血术中即刻缝合10例腹股沟(3.6%)。
- 术后并发症另见6例腹股沟(2.2%),其中2例患者(0.7%)接受追加外科手术。
关键数值与推荐
- 技术成功定义为MANTA部署后5分钟内成功闭合血管,无再出血且无需任何额外操作。
- 技术失败定义为术后30天内闭合装置失败、感染、出血、穿孔、下肢缺血、血肿>5 cm、血清肿、假性动脉瘤、动静脉瘘、远端栓塞、股动脉血栓形成和动脉夹层。
临床怎么用
- 在符合使用说明的经皮EVAR患者中,MANTA可作为安全有效的闭合装置选择。
- 术后30天需临床评估和CT血管造影随访以监测并发症。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Percutaneous endovascular aortic repair (pEVAR) has become the gold standard in the treatment of aortic aneurysms. Vascular puncture site complications can have severe implications on morbidity and mortality of patients, underlining the necessity for safe and effective closure devices. The MANTA vascular closure device (VCD) has shown to be safe and effective in patients undergoing endovascular aortic repair (EVAR) and transcatheter aortic valve replacement (TAVR). However, most of these trials were conducted in TAVR patients, involved highly selected populations, and had a retrospective design. This study aims to address the limited real-world data on the performance of the MANTA device in EVAR patients. METHODS: We performed a multicenter, prospective, observational, non-∖randomized study on the performance of the MANTA VCD (Teleflex Inc., Pennsylvania, USA) in patients receiving percutaneous EVAR. We selected patients within instructions for use of MANTA VCD. Time to hemostasis was measured. All patients had a clinical evaluation before discharge and at 30 days. A computed tomography angiography was performed at 30 days of index procedure. Primary outcome was technical success defined as successful vessel closure within 5 minutes after MANTA VCD deployment, without rebleeding and without the need of any additional procedures. Secondary outcome was technical failure defined as closure device failure, infection, bleeding, perforation, lower leg ischemia, hematoma >5 cm, seroma, pseudoaneurysm, arteriovenous fistula, distal embolization, femoral artery thrombosis, and arterial dissection within 30 days after the index procedure. RESULTS: Patient inclusion took place between January 2019 and November 2023. A total of 279 groins were treated with the MANTA VCD, and every patient received EVAR through femoral access. Technical success was seen in 263 groins (94.3%). Adverse events were seen in 16 groins (5.7%). The median time to hemostasis was 1 minute 0 seconds in both the right and left common femoral artery (interquartile range right: 11min10sec, left: 1m40sec). Immediate suture of the femoral artery during index procedure due to bleeding of the femoral artery was seen in 10 groins (3.6%). Postprocedural complications were seen in another 6 groins (2.2%) of which 2 patients (0.7%) received adjunctive surgical procedures. CONCLUSION: The MANTA VCD was found to be a safe and effective closure device in patient receiving pEVAR repair with a high technical success rate.
引用
- Goeteyn J, Jongen A, Loos M, et al. Outcome of a Prospective Registry to Evaluate the Performance of the MANTA Vascular Closure Device in EVAR Patients. Ann Vasc Surg. 2026. PMID: 41831821. doi:10.1016/j.avsg.2026.02.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。